表紙
市場調査レポート

経皮/皮内ドラッグデリバリー用マイクロニードル

Microneedles for Trans / Intradermal Drug Delivery

発行 ROOTS ANALYSIS 商品コード 317875
出版日 ページ情報 英文 210 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
経皮/皮内ドラッグデリバリー用マイクロニードル Microneedles for Trans / Intradermal Drug Delivery
出版日: 2014年10月29日 ページ情報: 英文 210 Pages
概要

マイクロニードルは大量の薬剤およびワクチンを輸送することが出来、技術は特に決まった薬剤に限られません。開発中の製品の70%以上が固形または吸収性の針を組み入れたパッチであり、残りはシリンジ用の空洞マイクロニードルアレイです。マイクロニードル製品の開発に参入している様々な企業のうち、約50%は様々な投資家から金融支援を受けている新興企業です。また、多くの大学機関も診断、遺伝子デリバリーおよび継続的薬剤モニタリングの目的でのマイクロニードル利用を研究しています。これらの研究プロジェクトの多数は、使いやすいウェアラブルパッチとしてのマイクロニードル製品の開発に力を注いでいます。2010年代末までにマイクロニードル型の治療製品がいくつか発売されるため、マイクロニードル型デリバリー装置の総市場は、2030年までに年間売上高が4億8,500万に達すると予測されています。

当レポートでは、治療用デリバリーシステムに基づいたマイクロニードル市場について調査し、従来型ニードルシリンジシステムに勝るマイクロニードル支援のドラッグデリバリーのメリット、主要な産業のステークホルダー、製造上の課題、および来る機会などの分析をまとめ、お届けいたします。

第1章 序文

第2章 エグゼクティブサマリー

第3章 マイクロニードルのイントロダクション

  • マイクロニードルとは
  • 発展の経緯
  • 経皮形態の薬剤投与の理由
  • マイクロニードル利用の必要性
  • 従来型ニードルベースのデリバリーの欠点
  • マイクロニードル型デリバリーシステムのメリット
  • マイクロニードルの種類

第4章 市場概要

  • 本章の概要
  • 経皮ドラッグデリバリーシステム
  • 製造
  • マイクロニードル技術プロバイダー
  • 近年の提携

第5章 技術プロバイダー

  • 本章の概要
  • Becton Dickinson (BD)
  • Clearside Biomedical
  • Corium International
  • NanoPass Technologies
  • Zosano Pharma
  • その他の技術プロバイダー

第6章 大学

  • 本章の概要
  • Queen's University Belfast
  • Emory and Georgia Technology
  • North Carolina State University and University of California, San Diego
  • University of Pittsburgh
  • University of Washington
  • Cardiff University

第7章 製品プロファイル

  • 本章の概要
  • Fluzone Intradermal, Sanofi Pasteur
  • Intanza, Sanofi Pasteur
  • Polio Vaccine, NanoPass Technologies
  • CLS-1001, Clearside Biomedical ?
  • Cat-SPIRE, Circassia
  • Abaloparatide-TD (BA058), Radius Health
  • CLS-1003, Clearside Biomedical
  • Ragweed-SPIRE, Circassia
  • Grass-SPIRE, Circassia
  • ZP-PTH Weekly, Zosano Pharma ?
  • MicroCor PTH, Corium International
  • HDM-SPIRE, Circassia
  • ZP-Glucagon, Zosano Pharma
  • H5N1 Avian Influenza VLP Vaccine, Medicago
  • 前臨床試験中の製品

第8章 ケーススタディ

  • 本章の概要
  • Rapid Infuser and V-Go (Valeritas, Inc.)
  • BD Libertas? Patch Injector (BD Medical)
  • Phillips Medisize Corporation

第9章 市場予測

  • 本章の概要
  • 範囲・制限
  • 予測手法
  • 全体的なドラッグデリバリー用マイクロニードル市場
  • Soluvia (Becton Dickinson)
  • Polio Vaccine (Nanopass Technologies)
  • CLS-1001 (Clearside Biomedical)
  • Cat-SPIRE (Circassia)
  • BA058 (Radius Health)
  • CLS-1003 (Clearside Biomedical)
  • Flu Vaccine Patch (Dr. Prausnitz Group)
  • Ragweed-SPIRE (Circassia)
  • Grass-SPIRE (Circassia)
  • ZP-PTH Weekly (Zosano Pharma)
  • MicroCor PTH (Corium International)
  • HDM-SPIRE (Circassia)
  • ZP-Glucagon (Zosano Pharma)

第10章 SWOT分析

  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 インタビュー記録

第12章 結論

第13章 付録1:表

第14章 付録2:企業・組織リスト

図表

目次
Product Code: RA10024

Transdermal delivery via microneedles is increasingly gaining traction as one of the more promising drug delivery technologies. Microneedles are of a few hundred microns in size, capable of creating transient pores across the skin by penetrating the stratum corneum layer to deliver molecules. These needles are not big enough to reach the nerve-rich regions of the skin; as a result, the drug delivery is perceived as completely painless and devoid of bleeding. Drugs, vaccines, proteins, peptides and other biomolecules are suitable for delivery using the microneedle technology.

The market is still in its infancy. So far, only one microneedle based delivery device, Soluvia prefilled microinjection system, has reached the market. The vaccine-device combination product was FDA approved in May 2011 for intradermal delivery of Fluzone influenza vaccine. We have identified more than 25 companies, with proprietary microneedle technology, actively working towards the development of microneedle-based drug or vaccine products. Clearside Biomedical, NanoPass Technologies, Corium International, Circassia, Radius Health and Zosano Pharma are examples of companies which are evaluating microneedle based drug/vaccine - device combination products (referred to as products hereafter) in clinical trials.

During the course of our research, we came across 22 products currently in different stages of development. We expect around ten products to be launched by the end of this decade, providing the much needed push to this market. Technological advancements will ensure the development of microneedle systems with improved safety and efficacy profile. As more products move from pipeline to the market, we expect to see an increase in the investment in this area from various quarters.

Synopsis

The ‘Microneedles for Transdermal and Intradermal Drug Delivery, 2014-2030' report provides an extensive study in the field of microneedle based delivery systems for therapeutic use. The report covers various aspects, such as, benefits of microneedle assisted drug delivery over conventional needle-syringe system, key industry stakeholders, manufacturing challenges and upcoming opportunities.

One of the key objectives of this report is to understand the current and future state of the microneedles market. This is done by analysing

  • Products currently available in the market and those under development (both clinical / pre-clinical)
  • Recent partnerships which have taken place over the last few years covering product co-development and technology licensing
  • Spin-off companies from academic institutions carrying forward the research work to develop end-user products
  • Competitive landscape and inherent threats to growth in the short and long term
  • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

The base year for the report is 2013. The study provides short-mid term and long term market forecasts for the period 2014 - 2022 and 2022 - 2030, respectively. The research, analysis and insights presented in this report include potential sales of microneedle based delivery devices based on the adoption of 13 marketed and pipeline products; this analysis is backed by a deep understanding of key drivers behind the growth.

Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

For the scope of our report, we have only considered the microneedle products intended for medicinal use and excluded the microneedle-based products which are directed towards cosmetic applications. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1. Microneedles can deliver a plethora of drugs and vaccines; the technology is not limited to any specific class of drugs. More than 70% of the products in development are patches incorporating solid or dissolvable needles, rest are hollow microneedle arrays which employ the use of a syringe.
  • 2. About 12 products based on microneedle technology are currently in clinical development, more than half of which are in phase II or a higher stage of development. In addition, there are a number of other products currently in preclinical trials.
  • 3. Amongst the various firms involved in developing microneedle products, almost 50% are start-ups, which have received financial support from various investors.
  • 4. Many academic institutions are also exploring the use of microneedles for diagnostics, gene delivery and continuous drug monitoring purposes. Majority of these research projects are focused in developing microneedle products as easy-to-use wearable patches.
  • 5. With several new microneedle based therapeutic product launches by the end of this decade, we expect the overall market for microneedle based delivery devices to reach annual sales of 485 million units by 2030.

Research Methodology

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 presents an executive summary of the report. It offers a high level view on where the microneedles market is headed in the mid-long term.

Chapter 3 provides a general introduction to microneedles for transdermal drug delivery. In this section we have discussed, in detail, the concept of microneedles, their historical evolution, mechanism of action and advantages over traditional needle syringes.

Chapter 4 provides an overview of the market landscape. This chapter includes comprehensive information on various technology providers, types of microneedle products, associated materials and manufacturing processes. Information regarding the partnerships that have taken place in the past few years has also been included in this chapter.

Chapter 5 focuses on the key technology providers which have proprietary microneedle technology, with special reference to companies which have microneedle based products under clinical stage of development. In addition to providing detailed profiles of five leading players in the industry, we have also looked at 13 other players which are currently focused in this market.

Chapter 6 discusses the notable microneedle based research work currently underway in academia. It includes comprehensive information on various universities, along with their projects, which have taken a keen interest in this emerging research area.

Chapter 7 provides insights on all the products that are currently marketed or being developed based on the microneedle technology. All these drugs / vaccines have been profiled in this chapter. Amongst other things, these profiles include information related to drug specifications, current stage of development, clinical trials details etc.

Chapter 8 includes case studies of two additional products that are based on microneedle technology but employ a different mode of administration. In addition, we have also profiled a contract manufacturer which manufactures microneedle using its proprietary micro molding technology.

Chapter 9 identifies the forecasted future opportunity presented by the microneedle market. It includes our sales estimates on individual products that are currently marketed or are likely to be available in the near future. We have provided three different growth scenarios for the time period 2014 - 2030.

Chapter 10 provides our analysis of the strengths, weaknesses, opportunities and threats influencing the overall market, capturing the key elements likely to determine future growth.

Chapter 11 is a collection of interview transcripts; these discussions have helped us in forming a better understanding of the key market dynamics, competitive landscape and the likely future trends.

Chapter 12 summarises the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures presented in the report.

Chapter 14 is an appendix, which lists down all the companies and organisations referenced in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION TO MICRONEEDLES

  • 3.1. What are Microneedles
  • 3.2. Historical Evolution
  • 3.3. Why Transdermal Mode of Drug Administration
  • 3.4. The Need for Using Microneedles
  • 3.5. Drawbacks of Conventional Needle Based Delivery
  • 3.6. Benefits of Microneedle Based Delivery System
  • 3.7. Types of Microneedles
    • 3.7.1. Solid Microneedles
    • 3.7.2. Hollow Microneedles
    • 3.7.3. Dissolvable Microneedles

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Transdermal Drug Delivery Systems
  • 4.3. Manufacturing
    • 4.3.1. MEMS Technology
    • 4.3.2. Micromilling Technology
  • 4.4. Microneedle Technology Providers
  • 4.5. Recent Partnerships

5. TECHNOLOGY PROVIDERS

  • 5.1. Chapter Overview
  • 5.2. Becton Dickinson (BD)
    • 5.2.1. Soluvia: Prefillable Microinjection System
    • 5.2.2. Marketing Approvals
    • 5.2.3. Sales Performance
    • 5.2.4. Partnerships
  • 5.3. Clearside Biomedical
    • 5.3.1. Microinjector
      • 5.3.1.1. Patents
      • 5.3.1.2. Manufacturing Capability
    • 5.3.2. Product Pipeline
    • 5.3.3. Funding
    • 5.3.4. Partnership
  • 5.4. Corium International
    • 5.4.1. MicroCor Technology
      • 5.4.1.1. Delivery Through an Applicator
      • 5.4.1.2. Manufacturing Capability
    • 5.4.2. Product Pipeline
    • 5.4.3. Sales Performance
    • 5.4.4. Partnership
    • 5.4.5. Funding
    • 5.4.6. Future Plans
  • 5.5. NanoPass Technologies
    • 5.5.1. MicronJet 600 Needle
      • 5.5.1.1. US and EU Device Approval
      • 5.5.1.2. Manufacturing Capabilities
    • 5.5.2. Product Pipeline
    • 5.5.3. Partnerships
    • 5.5.4. Funding
  • 5.6. Zosano Pharma
    • 5.6.1. ZP Patch Technology
      • 5.6.1.1. Applicator Device
    • 5.6.2. Product Pipeline
    • 5.6.3. Funding
    • 5.6.4. Partnerships
    • 5.6.5. Future Plans
  • 5.7. Other Technology Providers
    • 5.7.1. 3M Drug Delivery Systems
      • 5.7.1.1. Microneedle Technology
      • 5.7.1.2. Sales Performance
      • 5.7.1.3. Partnerships
    • 5.7.2. Apogee Technology
      • 5.7.2.1. PyraDerm
      • 5.7.2.2. Partnership
    • 5.7.3. BioSerenTach Inc.
      • 5.7.3.1. Dissolvable Microneedle (DM) Chip
      • 5.7.3.2. Recent Developments
    • 5.7.4. Debiotech
      • 5.7.4.1. DebioJect System
      • 5.7.4.2. Clinical Trials
      • 5.7.4.3. Partnerships and Awards
    • 5.7.5. FluGen
      • 5.7.5.1. Technology
      • 5.7.5.2. Funding
    • 5.7.6. Fujifilm
      • 5.7.6.1. Micro-Needle Array
      • 5.7.6.2. Sales Performance
    • 5.7.7. ImmuPatch
      • 5.7.7.1. ImmuPatch Technology
      • 5.7.7.2. Research and Funding
    • 5.7.8. Micropoint Technologies
      • 5.7.8.1. Microneedle Technology
      • 5.7.8.2. Funding
    • 5.7.9. nanoBioSciences
      • 5.7.9.1. AdminPen Injection System
    • 5.7.10. Nemaura Pharma
      • 5.7.10.1. Microneedle Technology
      • 5.7.10.2. Recent Developments
    • 5.7.11. TheraJect
      • 5.7.11.1. TheraJect MAT System
      • 5.7.11.2. Research and Funding
    • 5.7.12. Valeritas
      • 5.7.12.1. Micro-Trans Microneedle System
      • 5.7.12.2. Funding and Awards
    • 5.7.13. Vaxxas
      • 5.7.13.1. Nanopatch
      • 5.7.13.2. Partnership and Funding

6. ACADEMIA

  • 6.1. Chapter Overview
  • 6.2. Queen's University Belfast
    • 6.2.1. Microneedle Technology
    • 6.2.2. Advantages
    • 6.2.3. Awards and Opportunity
  • 6.3. Emory and Georgia Technology
    • 6.3.1. Microneedle Technology
    • 6.3.2. Research Programs
    • 6.3.3. Other Developments
  • 6.4. North Carolina State University and University of California, San Diego
    • 6.4.1. Research Programs
  • 6.5. University of Pittsburgh
    • 6.5.1. Research Programs
  • 6.6. University of Washington
    • 6.6.1. Research Programs
  • 6.7. Cardiff University
    • 6.7.1. Research Programs

7. PRODUCT PROFILES

  • 7.1. Chapter Overview
  • 7.2. Fluzone Intradermal, Sanofi Pasteur
    • 7.2.1. Regulatory Approvals
    • 7.2.2. Pricing
    • 7.2.3. Manufacturing
  • 7.3. Intanza, Sanofi Pasteur
    • 7.3.1. Regulatory Approval
  • 7.3.2. Manufacturing
  • 7.4. Polio Vaccine, NanoPass Technologies
    • 7.4.1. Increased use of IPV
    • 7.4.2. Microneedle Assisted IPV
    • 7.4.3. Clinical Trials
  • 7.5. CLS-1001, Clearside Biomedical
    • 7.5.1. Clinical Trials
    • 7.5.2. Future Plans
  • 7.6. Cat-SPIRE, Circassia
    • 7.6.1. ToleroMune Technology
    • 7.6.2. Partnership for Intradermal Delivery
    • 7.6.3. Clinical Trials
    • 7.6.4. Future Plans
  • 7.7. Abaloparatide-TD (BA058), Radius Health
    • 7.7.1. Clinical Trials
    • 7.7.2. Manufacturing
    • 7.7.3. Funding and Collaborations
    • 7.7.4. Future Plans
  • 7.8. CLS-1003, Clearside Biomedical
    • 7.8.1. Future Plans
  • 7.9. Ragweed-SPIRE, Circassia
    • 7.9.1. Clinical Trials
    • 7.9.2. Future Plans
  • 7.10. Grass-SPIRE, Circassia
    • 7.10.1. Clinical Trials
    • 7.10.2. Future Plans
  • 7.11. ZP-PTH Weekly, Zosano Pharma
    • 7.11.1. Clinical Trials
    • 7.11.2. Future Plans
  • 7.12. MicroCor PTH, Corium International
    • 7.12.1. Clinical Trials
    • 7.12.2. Future Plans
  • 7.13. HDM-SPIRE, Circassia
    • 7.13.1. Clinical Trials
    • 7.13.2. Future Plans
  • 7.14. ZP-Glucagon, Zosano Pharma
    • 7.14.1. Clinical Trials
    • 7.14.2. Future Plans
  • 7.15. H5N1 Avian Influenza VLP Vaccine, Medicago
    • 7.15.1. VLP Technology
    • 7.15.2. Intradermal Formulation
    • 7.15.3. Clinical Trials
  • 7.16. Products in Preclinical Trials

8. CASE STUDIES

  • 8.1. Chapter Overview
  • 8.2. Rapid Infuser and V-Go (Valeritas, Inc.)
    • 8.2.1. Introduction
    • 8.2.2. Rapid Infuser
      • 8.2.2.1. Key Features
      • 8.2.2.2. Advantages
    • 8.2.3. V-Go
      • 8.2.3.1. Key Features
      • 8.2.3.2. Advantages
  • 8.3. BD Libertas™ Patch Injector (BD Medical)
    • 8.3.1. Introduction
    • 8.3.2. Product Description
    • 8.3.3. Usage / Mechanism
    • 8.3.4. Advantages
    • 8.3.5. Current Status
  • 8.4. Phillips Medisize Corporation
    • 8.4.1. Company Overview
    • 8.4.2. Microneedle Based Drug Delivery
    • 8.4.3. Microneedle Manufacturing

9. MARKET FORECAST, 2014-2030

  • 9.1. Chapter Overview
  • 9.2. Scope and Limitations
  • 9.3. Forecast Methodology
  • 9.4. Overall Microneedles Market for Drug Delivery, 2014-2030
  • 9.5. Soluvia (Becton Dickinson)
    • 9.5.1. Soluvia Sales forecast: Short-Mid Term, 2014-2022
    • 9.5.2. Soluvia Sales forecast: Long Term, 2022-2030
  • 9.6. Polio Vaccine (Nanopass Technologies)
    • 9.6.1. Polio Vaccine Sales Forecast: Short-Mid Term, 2014-2022
    • 9.6.2. Polio Vaccine Sales Forecast: Long Term, 2022-2030
  • 9.7. CLS-1001 (Clearside Biomedical)
    • 9.7.1. CLS-1001 Sales Forecast: Short-Mid Term, 2014-2022
    • 9.7.2. CLS-1001 Sales Forecast: Long Term, 2022-2030
  • 9.8. Cat-SPIRE (Circassia)
    • 9.8.1. Cat-SPIRE Sales Forecast: Short-Mid Term, 2014-2022
    • 9.8.2. Cat-SPIRE Sales Forecast: Long Term, 2022-2030
  • 9.9. BA058 (Radius Health)
    • 9.9.1. BA058 Sales Forecast: Short-Mid Term, 2014-2022
    • 9.9.2. BA058 Sales Forecast: Long Term, 2022-2030
  • 9.10. CLS-1003 (Clearside Biomedical)
    • 9.10.1. CLS-1003 Sales Forecast: Short-Mid Term, 2014-2022
    • 9.10.2. CLS-1003 Sales Forecast: Long Term, 2022-2030
  • 9.11. Flu Vaccine Patch (Dr. Prausnitz Group)
    • 9.11.1. Flu Vaccine Patch Sales Forecast: Short-Mid Term, 2014-2022
    • 9.11.2. Flu Vaccine Patch Sales Forecast: Long Term, 2022-2030
  • 9.12. Ragweed-SPIRE (Circassia)
    • 9.12.1. Ragweed-SPIRE Sales Forecast: Short-Mid Term, 2014-2022
    • 9.12.2. Ragweed-SPIRE Sales Forecast: Long Term, 2022-2030
  • 9.13. Grass-SPIRE (Circassia)
    • 9.13.1. Grass-SPIRE Sales Forecast: Short-Mid Term, 2014-2022
    • 9.13.2. Grass-SPIRE Sales Forecast: Long Term, 2022-2030
  • 9.14. ZP-PTH Weekly (Zosano Pharma)
    • 9.14.1. ZP-PTH Weekly Sales Forecast: Short-Mid Term, 2014-2022
    • 9.14.2. ZP-PTH Weekly Sales Forecast: Long Term, 2022-2030
  • 9.15. MicroCor PTH (Corium International)
    • 9.15.1. MicroCor PTH Sales Forecast: Short-Mid Term, 2014-2022
    • 9.15.2. MicroCor PTH Sales Forecast: Long Term, 2022-2030
  • 9.16. HDM-SPIRE (Circassia)
    • 9.16.1. HDM-SPIRE Sales Forecast: Short-Mid Term, 2014-2022
    • 9.16.2. HDM-SPIRE Sales Forecast: Long Term, 2022-2030
  • 9.17. ZP-Glucagon (Zosano Pharma)
    • 9.17.1. ZP-Glucagon Sales Forecast: Short-Mid Term, 2014-2022
    • 9.17.2. ZP-Glucagon Sales Forecast: Long Term, 2022-2030

10. SWOT ANALYSIS

  • 10.1. Strengths
  • 10.2. Weakness
  • 10.3. Opportunities
  • 10.4. Threats

11. INTERVIEW TRANSCRIPTS

  • 11.1. Interview 1: Nemaura Pharma, Dr. Faz Chowdhury, CEO
  • 11.2. Interview 2: TheraJect, Dr. Sung Yun Kwon, CEO
  • 11.3. Interview 3: North Carolina State University, Dr. Roger Narayan, Professor
  • 11.4. Interview 4: Clearside Biomedical, Steve Lang, VP, Commercial Operations

12. CONCLUSION

  • 12.1. Microneedles: Alternative to Hypodermic Injections
  • 12.2. Academia is at the Forefront of Research; Spin-offs will Drive Commercial Applications
  • 12.3. Emerging Market, with A Huge Growth Potential
  • 12.4. Contract Manufacturers Likely to Play an Important Role in Realising the Ambition
  • 12.5. Concluding Remarks

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

List of Figures:

  • Figure 3.1: Viral Infection Cases Due to Unsafe Injections (in 000')
  • Figure 4.1: Transdermal Products: Distribution by Technology
  • Figure 4.2: Microneedle Devices: Distribution by Patches and Syringes
  • Figure 4.3: Microneedle Devices: Distribution by Type of Microneedle
  • Figure 5.1: BD: Sales, 2013-Q3, 2014 (USD Billion)
  • Figure 5.2: BD: 2013 Sales by Business Division (USD Billion)
  • Figure 5.3: BD Medical: 2013 Sales by Product Segment (USD Billion)
  • Figure 5.4: Corium: Sales Q2-Q3, 2014 (USD Million)
  • Figure 5.5: 3M: Sales, 2009-2013 (USD Billion)
  • Figure 5.6: Fujifilm: Sales, 2014 (JPY Billion)
  • Figure 7.1: Distribution of Marketed / Pipeline Products using Microneedle Systems
  • Figure 9.1: Overall Microneedle Market for Drug Delivery (Million Units), 2014 - 2030
  • Figure 9.2: Soluvia Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
  • Figure 9.3: Soluvia Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
  • Figure 9.4: Polio Vaccine Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
  • Figure 9.5: Polio Vaccine Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
  • Figure 9.6: CLS-1001 Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
  • Figure 9.7: CLS-1001 Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
  • Figure 9.8: Cat-SPIRE Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
  • Figure 9.9: Cat-SPIRE Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
  • Figure 9.10: BA058 Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
  • Figure 9.11: BA058 Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
  • Figure 9.12: CLS-1003 Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
  • Figure 9.13: CLS-1003 Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
  • Figure 9.14: Flu Vaccine Patch Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
  • Figure 9.15: Flu Vaccine Patch Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
  • Figure 9.16: Ragweed-SPIRE Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
  • Figure 9.17: Ragweed-SPIRE Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
  • Figure 9.18: Grass-SPIRE Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
  • Figure 9.19: Grass-SPIRE Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
  • Figure 9.20: ZP-PTH Weekly Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
  • Figure 9.21: ZP-PTH Weekly Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
  • Figure 9.22: MicroCor PTH Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
  • Figure 9.23: MicroCor PTH Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
  • Figure 9.24: HDM-SPIRE Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
  • Figure 9.25: HDM-SPIRE Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
  • Figure 9.26: ZP-Glucagon Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
  • Figure 9.27: ZP-Glucagon Sales Forecast (Million Units): Long Term, 2022-2030(Base Scenario)
  • Figure 12.1: Overall Microneedles Market for Drug Delivery (Million Units): 2104, 2022 and 2030

List of Tables:

  • Table 4.1: Approved Transdermal Drug Delivery Systems
  • Table 4.2: Top 30 MEMS Companies, 2012
  • Table 4.3: Microneedle Based Drug Delivery: Technology Providers
  • Table 4.4: Microneedle Based Drug Delivery: List of Partnerships
  • Table 5.1: Other Companies Active in the Field of Microneedles
  • Table 5.2: Soluvia: Approvals
  • Table 5.3: Clearside Biomedical: Product Portfolio
  • Table 5.4: Corium: Product Portfolio
  • Table 5.5: NanoPass Technologies: Product Portfolio
  • Table 5.6: Zosano Pharma: Product Portfolio
  • Table 5.7: AdminPen Pricing
  • Table 5.8: AdminPatch Array Pricing
  • Table 6.1: University Research Technologies
  • Table 7.1: Marketed or Pipeline Drugs/Vaccines using Microneedle Systems
  • Table 9.1: Microneedle Based Products: Expected Launch Timelines
  • Table 10.1: SWOT Analysis
  • Table 13.1: BD: Sales, 2013-Q3, 2014 (USD Billion)
  • Table 13.2: BD: 2013 Sales by Business Division (USD Billion)
  • Table 13.3: BD Medical: 2013 Sales by Product Segments (USD Billion)
  • Table 13.4: Corium: Sales Q2-Q3, 2014 (USD Million)
  • Table 13.5: 3M: Sales, 2009-2013 (USD Billion)
  • Table 13.6: Fujifilm: Sales, 2014 (JPY Billion)
  • Table 13.7: Overall Microneedle Market for Drug Delivery (Million Units), 2014-2030 (Base Scenario)
  • Table 13.8: Overall Microneedle Market for Drug Delivery (Million Units), 2014-2030 (Optimistic Scenario)
  • Table 13.9: Overall Microneedle Market for Drug Delivery (Million Units), 2014-2030 (Conservative Scenario)
  • Table 13.10: Soluvia Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
  • Table 13.11: Soluvia Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
  • Table 13.12: Soluvia Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
  • Table 13.13: Soluvia Sales Forecast: Long Term, 2022-2030 (Base Scenario)
  • Table 13.14: Soluvia Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
  • Table 13.15: Soluvia Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
  • Table 13.16: Polio Vaccine Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
  • Table 13.17: Polio Vaccine Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
  • Table 13.18: Polio Vaccine Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
  • Table 13.19: Polio Vaccine Sales Forecast: Long Term, 2022-2030 (Base Scenario)
  • Table 13.20: Polio Vaccine Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
  • Table 13.21: Polio Vaccine Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
  • Table 13.22: CLS-1001 Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
  • Table 13.23: CLS-1001 Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
  • Table 13.24: CLS-1001 Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
  • Table 13.25: CLS-1001 Sales Forecast: Long Term, 2022-2030 (Base Scenario)
  • Table 13.26: CLS-1001 Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
  • Table 13.27: CLS-1001 Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
  • Table 13.28: Cat-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
  • Table 13.29: Cat-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
  • Table 13.30: Cat-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
  • Table 13.31: Cat-SPIRE Sales Forecast: Long Term, 2022-2030 (Base Scenario)
  • Table 13.32: Cat-SPIRE Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
  • Table 13.33: Cat-SPIRE Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
  • Table 13.34: Abaloparatide-TD Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
  • Table 13.35: Abaloparatide-TD Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
  • Table 13.36: Abaloparatide-TD Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
  • Table 13.37: Abaloparatide-TD Sales Forecast: Long Term, 2022-2030 (Base Scenario)
  • Table 13.38: Abaloparatide-TD Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
  • Table 13.39: Abaloparatide-TD Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
  • Table 13.40: CLS-1003 Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
  • Table 13.41: CLS-1003 Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
  • Table 13.42: CLS-1003 Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
  • Table 13.43: CLS-1003 Sales Forecast: Long Term, 2022-2030 (Base Scenario)
  • Table 13.44: CLS-1003 Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
  • Table 13.45: CLS-1003 Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
  • Table 13.46: Flu Vaccine Patch Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
  • Table 13.47: Flu Vaccine Patch Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
  • Table 13.48: Flu Vaccine Patch Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
  • Table 13.49: Flu Vaccine Patch Sales Forecast: Long Term, 2022-2030 (Base Scenario)
  • Table 13.50: Flu Vaccine Patch Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
  • Table 13.51: Flu Vaccine Patch Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
  • Table 13.52: Ragweed-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
  • Table 13.53: Ragweed-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
  • Table 13.54: Ragweed-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
  • Table 13.55: Ragweed-SPIRE Sales Forecast: Long Term, 2022-2030 (Base Scenario)
  • Table 13.56: Ragweed-SPIRE Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
  • Table 13.57: Ragweed-SPIRE Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
  • Table 13.58: Grass-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
  • Table 13.59: Grass-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
  • Table 13.60: Grass-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
  • Table 13.61: Grass-SPIRE Sales Forecast: Long Term, 2022-2030 (Base Scenario)
  • Table 13.62: Grass-SPIRE Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
  • Table 13.63: Grass-SPIRE Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
  • Table 13.64: ZP-PTH Weekly Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
  • Table 13.65: ZP-PTH Weekly Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
  • Table 13.66: ZP-PTH Weekly Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
  • Table 13.67: ZP-PTH Weekly Sales Forecast: Long Term, 2022-2030 (Base Scenario)
  • Table 13.68: ZP-PTH Weekly Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
  • Table 13.69: ZP-PTH Weekly Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
  • Table 13.70: MicroCor-PTH Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
  • Table 13.71: MicroCor-PTH Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
  • Table 13.72: MicroCor-PTH Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
  • Table 13.73: MicroCor-PTH Sales Forecast: Long Term, 2022-2030 (Base Scenario)
  • Table 13.74: MicroCor-PTH Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
  • Table 13.75: MicroCor-PTH Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
  • Table 13.76: HDM-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
  • Table 13.77: HDM-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
  • Table 13.78: HDM-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
  • Table 13.79: HDM-SPIRE Sales Forecast: Long Term, 2022-2030 (Base Scenario)
  • Table 13.80: HDM-SPIRE Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
  • Table 13.81: HDM-SPIRE Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
  • Table 13.82: ZP-Glucagon Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
  • Table 13.83: ZP-Glucagon Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
  • Table 13.84: ZP-Glucagon Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
  • Table 13.85: ZP-Glucagon Sales Forecast: Long Term, 2022-2030 (Base Scenario)
  • Table 13.86: ZP-Glucagon Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
  • Table 13.87: ZP-Glucagon Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)

List of Companies:

The following companies have been mentioned in this report.

  • 1. 10X Technology
  • 2. 3M Drug Delivery Systems
  • 3. 3M Unitek
  • 4. 4P Therapeutics
  • 5. AAC
  • 6. Abingworth
  • 7. Advanced Technology Ventures
  • 8. Agate Medical Investments
  • 9. AKM
  • 10. AllTranz
  • 11. Alza Corporation
  • 12. Amspar B.V
  • 13. Analog Devices
  • 14. Angiomed
  • 15. Aphelion Capital
  • 16. Apogee Technology
  • 17. Asahi Kasei Pharma Corporation (AKP)
  • 18. AvagoTechnologies
  • 19. Bausch & Lomb
  • 20. BB Biotech Ventures
  • 21. Becton Dickinson
  • 22. Biacore
  • 23. Biochemics
  • 24. BioMed Ventures
  • 25. BioSerenTach
  • 26. Biotech Growth N.V
  • 27. Bosch
  • 28. Brandon Capital
  • 29. Brookside Capital
  • 30. Canon
  • 31. Capital Royalty L.P
  • 32. Carrera
  • 33. CEA-LETI
  • 34. Cerametal
  • 35. CHL Medical Partners
  • 36. Circassia
  • 37. Clearside Biomedical
  • 38. Corium International
  • 39. Curasen
  • 40. Debiotech
  • 41. Denso
  • 42. D-Partners
  • 43. Elcam Medical
  • 44. Enterprise Ireland
  • 45. Essex Woodlands Health Ventures
  • 46. Extraject Technologies
  • 47. F2 Biosciences III, L.P.
  • 48. Flir Systems
  • 49. FluGen
  • 50. Forma Medical
  • 51. Fraunhofer Institute
  • 52. Freescale Semiconductor
  • 53. Fujifilm
  • 54. GE Sensing
  • 55. Georgia Research Alliance Venture Fund
  • 56. GSK
  • 57. Hatteras Venture Partners
  • 58. HBM BioVentures
  • 59. HBM Partners
  • 60. HealthCare Ventures
  • 61. Hewlett Packard
  • 62. HLM Venture Partners
  • 63. Honeywell
  • 64. IBM
  • 65. ImmuPatch
  • 66. Infineon Technologies
  • 67. Invensense
  • 68. Ipsen Pharma
  • 69. Iscar
  • 70. Israel HealthCare Ventures (IHCV)
  • 71. Janisys
  • 72. Janssen Pharmaceuticals
  • 73. Kaiser Permanente Ventures
  • 74. Kenan Flagler Business School Private Equity Fund
  • 75. Kionix
  • 76. Knowles Electronics
  • 77. Knox LLC
  • 78. Lexmark
  • 79. Lonza Group Ltd.
  • 80. Macroflux Corporation
  • 81. Measurement Specialities Inc.
  • 82. Mecaplast
  • 83. Medicago
  • 84. Memsic
  • 85. Mercatus Capital and GITP (Global Innovations & Technology Platform) Investments
  • 86. Merck
  • 87. Metalor Dental
  • 88. MicroCreate B.V
  • 89. Micropoint Technologies
  • 90. Mountain Group Capital
  • 91. MPM Capital
  • 92. Murata
  • 93. nanoBioSciences
  • 94. Nanopass
  • 95. Nemaura Pharma
  • 96. New Enterprise Associates (NEA)
  • 97. Nissha Printing Co. Ltd
  • 98. Nomura Phase4 Ventures
  • 99. Novartis
  • 100. Novo Nordisk
  • 101. Novosanis
  • 102. Ofer Hi-Tech
  • 103. Omron
  • 104. OneVentures
  • 105. ONSET Ventures
  • 106. Oxford NanoDelivery
  • 107. Panasonic
  • 108. Par Pharmaceuticals
  • 109. Philips Medisize
  • 110. Phillips Plastic Corporation
  • 111. Phonak AG
  • 112. Pitango Venture Capital
  • 113. PKA SoftTouch Corp
  • 114. Procter & Gamble
  • 115. Pro-micron
  • 116. ProQuest Investments
  • 117. Quantum Technology Partners
  • 118. Radius Health
  • 119. Robert Bosch
  • 120. Rolex
  • 121. RusanoMedInvest (RMI)
  • 122. Sanofi Pasteur
  • 123. Santen Inc.
  • 124. Seco
  • 125. Seiko Epson
  • 126. Sensata
  • 127. Sony
  • 128. ST Microelectronics
  • 129. Star Surgical
  • 130. StrataGent Life Sciences
  • 131. TechnoPhage
  • 132. Teva Pharmaceuticals
  • 133. Texas Instruments
  • 134. TheraJect
  • 135. TransDerm Inc.
  • 136. Triquint
  • 137. Tyco Electronics
  • 138. Ulis
  • 139. UTC Aerospace
  • 140. Valeritas
  • 141. Vaxxas
  • 142. Welsh, Carson, Anderson & Stowe (WCAS)
  • 143. WFD Ventures
  • 144. Zosano Pharma
  • The following organisations have been mentioned in this report.
  • 1. Cardiff University
  • 2. Emory University
  • 3. European Medicines Agency (EMA)
  • 4. Food and Drug Administration (FDA)
  • 5. Georgia Institute of Technology
  • 6. Georgia Research Alliance
  • 7. Health Canada
  • 8. Imperial College, London
  • 9. Infectious Disease Research Institute (IDRI)
  • 10. Institute of Materials Research & Engineering
  • 11. Juvenile Diabetes Research Foundation (JDRF)
  • 12. Kyoto Pharmaceutical University
  • 13. National Institutes of Health (NIH)
  • 14. National Science Foundation
  • 15. North Carolina State University
  • 16. Oxford University
  • 17. PATH
  • 18. Queen's University Belfast
  • 19. Royal Institute of Technology, Stockholm
  • 20. Shanghai Institute of MateriaMedica (SIMM)
  • 21. St. Jude Children's Research Hospital
  • 22. Technology Strategy Board
  • 23. Tyndall National Institute
  • 24. University College Cork (UCC)
  • 25. University of California
  • 26. University of Melbourne
  • 27. University of Pittsburgh
  • 28. University of Queensland
  • 29. University of Washington
  • 30. University of Wisconsin, Madison
  • 31. Vaccine and Immunotherapy Centre of the Centre Hospitalier Universitaire Vaudois (CHUV)
  • 32. Vaccine and Infectious Disease Organization (VIDO)
  • 33. World Health Organization (WHO)
Back to Top